Nanovaccine plus immunotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new vaccine (ONVAX-01) combined with an immune-boosting drug and chemotherapy for pancreatic cancer that has spread and contains a KRAS mutation. The vaccine is designed to train your immune system to fight cancer cells while the other drugs help enhance this effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Advanced pancreatic cancer (KRAS-mutated, metastatic) that has grown despite at least one prior treatment
- Able to perform light daily activities (ECOG status 0 or 1)
- Measurable tumors visible on recent imaging (within 28 days)
- Adequate blood counts, kidney, and liver function without recent transfusions or growth factors
- No prior checkpoint inhibitor therapy (anti-PD-1, anti-PD-L1, or similar immune drugs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an oncolytic virus (a virus that targets cancer cells), an immunotherapy drug (anti-PD1), and chemotherapy given before surgery for people with borderline resectable or locally advanced pancreatic cancer. The goal is to see if this approach can shrink the tumor enough to make surgery more successful.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a new drug called onvansertib combined with standard chemotherapy (NALIRIFOX) as the first treatment for advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to see if adding onvansertib helps shrink tumors or slow the cancer better than chemo alone.
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
This trial tests a combination of an oncolytic virus (a virus that attacks cancer cells) and a PD-1 inhibitor (an immunotherapy drug) for people with advanced pancreatic cancer that has not responded to at least two prior treatments.
This study tests a more frequent schedule of the experimental drug VCN-01 along with standard chemotherapy (nab-paclitaxel and gemcitabine) for people newly diagnosed with pancreatic cancer that has spread. The goal is to see if the virus-based therapy can help shrink tumors better.
Hear when a new Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.